Gilead signs HIV PrEP partnership with PAHO in Latin America

Gilead Sciences announced a new agreement with the Pan American Health Organization to expand access to HIV pre‑exposure prophylaxis across Latin American markets. The partnership aims to leverage Gilead's existing PrEP products and PAHO's regional health networks to increase treatment availability.

The deal focuses on scaling distribution, supporting local health initiatives, and potentially lowering costs for patients in the region. Gilead highlighted the collaboration as part of its broader strategy to address the HIV epidemic in underserved populations.

The briefing also noted other industry updates, including Hong Kong's investigation of the Cloudbreak IPO and brief mentions of VaxThera, Sironax, Circle Pharma, Nutshell Therapeutics, Evopoint, and Sensorion.